A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3503 participants.
Also called NCT02145468
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 3,503 participants
- Registry
-
NCT02145468
-
- Other papers using this trial's data
- Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Bulgaria, Canada, Chile, Czechia, Denmark, Estonia, France, Germany, Greece, Hong Kong SAR China, Hungary, Israel, Italy, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02145468. Randomized; double masking; primary purpose treatment. Start 2014-06-03 (actual); primary completion 2015-12-14 (actual). Results posted on 2017-06-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
- Acronym
- LATITUDE
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Losmapimod 7.5 mg twice daily
- Intervention (Drug)
- Placebo twice daily
- Intervention (Drug)
- Standard therapy
- Lead sponsor
- GlaxoSmithKline
- Collaborator
- The TIMI Study Group
Record details
- Record id
cardio:ct-nct02145468- Content hash
015679438d4f6437ebab028f1dd90129fb41c3bfec8bae1c512fed129da0d8d6